jeudi 5 avril 2018

Onco Actu du 5 avril 2018

1. Biologie

Genomic analysis uncovers prevalence of RNA splicing mutations in 33 tumor types [FierceBiotech]

Squeaky clean mice could be ruining research [Nature]

How CRISPR works, explained in two minutes [STAT]

2. Etiologie

California needs to stop saying everything causes cancer [Popular Science]

3.1.1 Prévention - Tabac - e-cigs

The Formaldehyde in Your E-Cigs [NY Times]

4.1 Dép., diag. & prono. - Prostate

Researchers to investigate screening for prostate cancer using MRI [Imperial College]

4.2 Dép., diag. & prono. - Génome

Foundation Medicine Announces Commercial Availability of FoundationOne CDx™, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion Diagnostics [Foundation Medicine]

5. Traitements

Seeing the future of radiotherapy in the MR Linac [Institute of Cancer Research]

5.1 Traitements - Pré-clinique

Two-drug approach halts lung tumors by starving them metabolically [Boston Children's Hospital]

5.12 Immunothérapies

Who Gets Immunotherapy for Cancer? [GEN]

Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response [NCI]

5.12.1 Immunothérapies - partenariats

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors [Boehringer Ingelheim]

Boehringer, OSE tie up in I-O deal that could total more than $1.4B [FierceBiotech]

Boehringer Ingelheim is thinking in blockbuster terms as it throws its hat into the ever-widening CD47 ring [EndPoints]

5.12.2 Immunothérapies - CAR-T

CAR T-Cell Therapy in ALL: Formidible Challenges Remain [Cancer Network]

5.2 Pharma

Eli Lilly's Cyramza rallies back in liver cancer with biomarker win [FiercePharma]

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations [Pfizer]

Riding a wave of positive PhIII readouts, Pfizer gets a snap review for lung cancer drug dacomitinib [EndPoints]

Lilly's Cyramza succeeds in late-stage liver cancer trial [Reuters]

5.2.3 Pharma - économie

Biopharma caught in the crosshairs of U.S.-China trade tussle [FiercePharma]

On the heels of major Pfizer deal, Arvinas snags $55M Series C for protein degradation cancer programs [EndPoints]

5.4 Traitements - Economie

Oncologists disagree on use of value to guide cancer treatments [Stanford Medicine]

5.9.8 AACR - Pharma

AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC [AstraZeneca]

6.4 Médico-éco

How much is too much? What does the US actually spend on health care administration? [The Incidental Economist]

6.6 Publications

The proportion of co-authored research articles has risen markedly in recent decades [LSE Impact Blog]

Nature: the truth [Nature]

Everything* You Always Wanted To Know About Blockchain (But Were Afraid To Ask) [The Scholarly Kitchen]

6.9 Controverses

EU copyright reforms draw fire from scientists [Nature]